Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
In Vivo ; 33(2): 621-626, 2019.
Article in English | MEDLINE | ID: mdl-30804150

ABSTRACT

AIM: To present the experience of the upper Gastrointestinal Unit of the Surgical Department of National and Kapodistrian University of Athens in order to inform surgeons of the exact harms and benefits associated with their decisions concerning management of antiplatelet therapy. MATERIALS AND METHODS: This was a single-center study of patients who underwent surgery for esophageal cancer and had concomitant coronary artery disease from 1/1/2005 to 31/7/2017. Patients were divided into two cohorts based on when their antiplatelet therapy was stopped (<7 vs. ≥7 days). Esophageal cancer was classified as esophageal only or as Siewert type I, II, or III based on tumor location at the gastroesophageal junction. A univariate logistic regression model was developed to assess the relationship between baseline variables and myocardial infraction, mortality, bleeding and stroke after the operation. For all tests, differences with a value of p<0.05 were considered significant. RESULTS: During the study period, 135 esophagectomies were performed for esophageal cancer. Almost 17% of them had concomitant coronary artery disease medically managed with antiplatelet therapy. No difference was found in terms of myocardial infarction, stroke or severe bleeding events between patients that stopped antiplatelet therapy for more or less than 7 days before esophagectomy. CONCLUSION: It is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.


Subject(s)
Coronary Artery Disease/drug therapy , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/surgery , Platelet Aggregation Inhibitors/administration & dosage , Aged , Clopidogrel/administration & dosage , Coronary Artery Disease/complications , Coronary Artery Disease/physiopathology , Esophageal Neoplasms/complications , Esophageal Neoplasms/physiopathology , Female , Hemorrhage/physiopathology , Humans , Male , Middle Aged , Perioperative Care , Platelet Aggregation Inhibitors/adverse effects , Risk Assessment , Risk Factors , Stents/adverse effects , Ticlopidine/administration & dosage , Ticlopidine/adverse effects
2.
Front Surg ; 5: 12, 2018.
Article in English | MEDLINE | ID: mdl-29564329

ABSTRACT

This is a report of a case who was admitted and operated on for a strangulated femoral hernia. The hernia sac contained a gangrenous appendix, which was excised and the hernia was repaired with sutures without complication. De Garengeot's hernia, although very rare, should be included in the differential diagnosis of cases with strangulated hernia and should receive the optimal treatment.

3.
Chirurgia (Bucur) ; 111(6): 513-516, 2016.
Article in English | MEDLINE | ID: mdl-28044955

ABSTRACT

A 73-year old woman was operated on with diffuse peritonitis and multiple abscesses throughout the mesentery which were drained. After the operation the patient could not recover. After an indicative computerized tomography the patient was re-explored. Perforation of the ileum and gastric perforation at the pylorus were found. There was no history of underline disease. The double perforation of the GI tract was surgically managed but the patient's course was fatal.


Subject(s)
Gastrectomy , Ileum , Intestinal Perforation/microbiology , Peritonitis/complications , Pyloric Antrum/pathology , Stomach Rupture/microbiology , Aged , Fatal Outcome , Female , Gastrectomy/methods , Humans , Ileum/surgery , Intestinal Perforation/diagnosis , Intestinal Perforation/surgery , Peritonitis/diagnosis , Peritonitis/surgery , Pyloric Antrum/surgery , Stomach Rupture/diagnosis , Stomach Rupture/surgery
SELECTION OF CITATIONS
SEARCH DETAIL